|
Camille Samuels joined Versant shortly after its formation in late 1999. She has been actively involved in Versant's investments in Biospect, Fluidigm, Genomic Health, Novacea, ParAllele, Reliant Pharmaceuticals and Syrrx. Prior to Versant, Ms. Samuels was a Director of Business Development at Tularik Inc., where she was responsible for corporate strategy and developing partnerships around clinical and preclinical therapeutic programs. She also led Tularik's Technology Acquisition Group, a group that was charged with retaining the company's technological advantage. Before Tularik, Ms. Samuels worked in business development/strategic planning at Millennium Pharmaceuticals (Predictive Medicine Division) and Genzyme Corporation. Ms. Samuels started her career as an Associate Consultant with LEK Consulting, providing management consulting and M&A advisory services primarily to healthcare clients. Ms. Samuels earned a bachelor's degree in biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar. In 2002, The Aspen Institute named Ms. Samuels a Henry Crown Fellow. | 